Dear colleagues,
Ongoing advances continue to refine the management of patients with diffuse large B-cell lymphoma (DLBCL). Data presented at the most recent ASH Annual Meeting provided substantial evidence on the role of bispecific antibodies and CAR T-cell therapies, both from pivotal clinical trials and real-world experience, further reinforcing immunotherapy as a key component of contemporary DLBCL treatment.
Current discussions increasingly focus on rational combination strategies, optimized management of immune-based therapies, and the appropriate sequencing of available treatment modalities across different disease settings.
With our DLBCL Congress, we are pleased to offer a scientific platform for multidisciplinary exchange, critical discussion of emerging data, and shared learning among colleagues, with the goal of translating evidence into clinical practice.
We warmly invite you to participate — either on site in Würzburg or live via online stream — and look forward to a highly informative meeting and a stimulating exchange of perspectives.
Best regards,
Johannes Düll
Senior physician
Universitätsklinik Würzburg
With the kind support of our sponsors:
Mit dem CMEducation.de-Newsletter erhalten Sie regelmäßige Informationen zu neuen Veranstaltungen von CMEducation.de
